Financial Metrics (as of 5/19/25): Price: $62.34 Market Cap: $13.93 billion Shares: ~223 million, fully diluted: ~246 million FCF/Share: 1.11 FCF Yield: 1.79% SBC Adjusted FCF/Share: 0.66 SBC Adjusted FCF Yield: 1.06% Forward FCF/Share = 1.22 FWD FCF Yield: 1.96 FWD EV/Sales: 5.77 Price/Sales: 8.11 FWD Price/Sales: 5.88 Q1 2025 Earnings Highlights: HIMS continues to deliver
At this concentration, biochemical parameters were also highest, including chl a (15.610.10 g g -1 FW), chl b (7.910.20 g g -1 FW), total chl (23.530.23 g g -1 FW), and carotenoids (27.530.63 g g -1 FW) in dimethyl sulfoxide (DMSO) extract, total soluble sugar (6.300.12 mg g -1 FW), proline (0.380.009 M g -1 FW), free radical scavenging activity (70.490.12%), total phenolics (6.610.02 g GAE g -1 FW), and total flavonoids (13.160.25 g QE g -1 FW)
Future work will need to clarify optimal timing, dosing, and treatment duration, as well as identify which patients derive the greatest benefit from GLP-1 based neuroprotection
Eligibility Criteria: BMI and Health Conditions Eden's semaglutide program considers specific requirements, primarily your BMI (Body Mass Index)
